Free Trial

Neuronetics (STIM) Stock Price, News & Analysis

Neuronetics logo
$3.33 -0.11 (-3.20%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$3.33 0.00 (0.00%)
As of 08/29/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Neuronetics Stock (NASDAQ:STIM)

Key Stats

Today's Range
$3.18
$3.48
50-Day Range
$3.20
$4.66
52-Week Range
$0.52
$5.92
Volume
1.47 million shs
Average Volume
1.63 million shs
Market Capitalization
$220.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Buy

Company Overview

Neuronetics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

STIM MarketRank™: 

Neuronetics scored higher than 38% of companies evaluated by MarketBeat, and ranked 736th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Neuronetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Neuronetics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Neuronetics' stock forecast and price target.
  • Earnings Growth

    Earnings for Neuronetics are expected to grow in the coming year, from ($1.13) to ($0.82) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Neuronetics is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Neuronetics is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Neuronetics has a P/B Ratio of 6.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Neuronetics' valuation and earnings.
  • Percentage of Shares Shorted

    7.87% of the float of Neuronetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Neuronetics has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Neuronetics has recently increased by 0.85%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Neuronetics does not currently pay a dividend.

  • Dividend Growth

    Neuronetics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.87% of the float of Neuronetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Neuronetics has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Neuronetics has recently increased by 0.85%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Neuronetics has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.05 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Neuronetics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 2 people have searched for STIM on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Neuronetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Neuronetics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.70% of the stock of Neuronetics is held by insiders.

  • Percentage Held by Institutions

    53.59% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Neuronetics' insider trading history.
Receive STIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

STIM Stock News Headlines

“HELIOS”: My No. 1 Investment of the 2020s
A mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druckenmiller — just raised nearly $1 billion in funding. Early backers believe it could be one of the most impactful breakthroughs of our lifetime. Whitney Tilson calls it “Helios” — and says a tiny Massachusetts firm sits at the center of what could become a global investment megatrend. If he’s right, this could mark the start of a seismic shift in how the world powers its future.tc pixel
See More Headlines

STIM Stock Analysis - Frequently Asked Questions

Neuronetics' stock was trading at $1.61 at the start of the year. Since then, STIM shares have increased by 106.8% and is now trading at $3.33.

Neuronetics, Inc. (NASDAQ:STIM) posted its quarterly earnings results on Tuesday, August, 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by $0.07. The company earned $38.11 million during the quarter, compared to analyst estimates of $36.80 million. Neuronetics had a negative net margin of 43.47% and a negative trailing twelve-month return on equity of 156.36%.
Read the conference call transcript
.

Neuronetics (STIM) raised $75 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Neuronetics' top institutional shareholders include Balyasny Asset Management L.P. (2.28%), Geode Capital Management LLC (1.33%), Boothbay Fund Management LLC (0.51%) and Massar Capital Management LP (0.33%). Insiders that own company stock include Cannell Capital Llc, Keith J Sullivan, William Andrew Macan, Robert Cascella, Stephen Furlong and Glenn P Muir.
View institutional ownership trends
.

Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neuronetics investors own include Gilead Sciences (GILD), SCYNEXIS (SCYX), Pfizer (PFE), GE Aerospace (GE), Intel (INTC), Bank of America (BAC) and Nokia (NOK).

Company Calendar

Last Earnings
8/05/2025
Today
8/30/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:STIM
CIK
1227636
Employees
180
Year Founded
N/A

Price Target and Rating

High Price Target
$7.00
Low Price Target
$7.00
Potential Upside/Downside
+110.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.13)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$43.71 million
Net Margins
-43.47%
Pretax Margin
-43.70%
Return on Equity
-156.36%
Return on Assets
-35.69%

Debt

Debt-to-Equity Ratio
1.76
Current Ratio
2.02
Quick Ratio
1.84

Sales & Book Value

Annual Sales
$74.89 million
Price / Sales
2.94
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.48 per share
Price / Book
6.94

Miscellaneous

Outstanding Shares
66,120,000
Free Float
60,372,000
Market Cap
$220.18 million
Optionable
Optionable
Beta
1.78

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:STIM) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners